Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefazolin Sodium

FDA-approved product (injectable, injection), marketed as Ancef, Ancef In Dextrose 5% In Plastic Container, Ancef In Plastic Container and 5 more.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cefazolin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Endocarditis
  • Infection
  • Prostatitis
  • Sepsis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
First-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DB04

Repurposing investigation

Cefazolin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA78.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli88.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • K. pneumoniae90.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis45.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 2 of 4 lab records
Open Cefazolin Sodium in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefazolin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Azithromycin for Cerclage Prophylaxis

    NCT07608562 · start 2026-09

    Registered record
    Registry ID
    NCT07608562
    Conditions
    Cervical Insufficiency
    Interventions
    Azithromycin Prophylaxis; Azithromycin Placebo; Cefazolin; Progesterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2028-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCervical Insufficiency
    InterventionAzithromycin Prophylaxis; Azithromycin Placebo; Cefazolin; Progesterone
    PhasePhase 4
    Registry statusNot yet recruiting

  • Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

    NCT07376889 · start 2026-02-01

    Registered record
    Registry ID
    NCT07376889
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2029-01
    Enrolment
    2,096

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionAntibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    PhasePhase 4
    Registry statusRecruiting

  • Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre

    NCT07033039 · start 2026-01-30

    Registered record
    Registry ID
    NCT07033039
    Conditions
    Rhinoplasty; Edema
    Interventions
    Photobiomodulation; Simulation of Photobiomodulation; Standard treatment protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-01-30
    Completion
    2030-11-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinoplasty; Edema
    InterventionPhotobiomodulation; Simulation of Photobiomodulation; Standard treatment protocol
    PhaseNot applicable
    Registry statusRecruiting

  • Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

    NCT06406114 · start 2025-05-05

    Registered record
    Registry ID
    NCT06406114
    Conditions
    Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy; Beta Lactam Adverse Reaction; Drug-Induced Anaphylaxis; Cephalosporin Reaction
    Interventions
    Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge; Amoxicillin double-blind placebo-controlled drug challenge
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2028-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy +3 more
    InterventionBeta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge +1 more
    PhasePhase 2
    Registry statusRecruiting

  • PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network

    NCT06920147 · start 2025-05-01

    Registered record
    Registry ID
    NCT06920147
    Conditions
    Surgical Site Infection
    Interventions
    Ertapenem; Cefazolin and Metronidazole.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2027-03-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Site Infection
    InterventionErtapenem; Cefazolin and Metronidazole.
    PhasePhase 4
    Registry statusNot yet recruiting

  • Post-Operative Antibiotic Efficacy in Clean Contaminated Head and Neck Surgery: A Randomized Controlled Trial

    NCT06672471 · start 2024-11-15

    Registered record
    Registry ID
    NCT06672471
    Conditions
    Head and Neck Neoplasms; UADT Neoplasm; Cancer of the Head and Neck; Antibiotic Resistant Infection; Antibiotic Side Effect
    Interventions
    No Post Operative Antibiotics for intervention group; Post Operative Antibiotics for one day
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2024-11-15
    Completion
    2025-10
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Neoplasms; UADT Neoplasm; Cancer of the Head and Neck; Antibiotic Resistant Infection +1 more
    InterventionNo Post Operative Antibiotics for intervention group; Post Operative Antibiotics for one day
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement

    NCT06814223 · start 2024-10-28

    Registered record
    Registry ID
    NCT06814223
    Conditions
    Infection Catheter-Related
    Interventions
    • Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-10-28
    Completion
    2028-06-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Catheter-Related
    Intervention• Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA
    PhasePhase 4
    Registry statusRecruiting

  • The Role of Antibiotic Prophylaxis in Lowering Wound Infection Rates Post-Open Repair of Primary Elective Groin Hernias in High-Risk Patients

    NCT06576154 · start 2024-08-01

    Registered record
    Registry ID
    NCT06576154
    Conditions
    Antibiotic Prophylaxis; Wound Infection; Groin Hernia
    Interventions
    Cefazolin 1000 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-08-01
    Completion
    2025-09-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Prophylaxis; Wound Infection; Groin Hernia
    InterventionCefazolin 1000 MG
    PhasePhase 3
    Registry statusUnknown

  • Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia

    NCT06336824 · start 2024-06-28

    Registered record
    Registry ID
    NCT06336824
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-06-28
    Completion
    2025-06
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionTab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    PhasePhase 3
    Registry statusUnknown

  • Randomized Assessment of Antibiotic Prophylaxis Prior to Port Placement

    NCT05304871 · start 2024-01

    Registered record
    Registry ID
    NCT05304871
    Conditions
    Vascular Access Ports
    Interventions
    Cefazolin; saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2024-01
    Completion
    2027-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVascular Access Ports
    InterventionCefazolin; saline
    PhaseNot applicable
    Registry statusWithdrawn

  • Antibiotic Prophylaxis in Pediatric Open Fractures

    NCT06055712 · start 2023-09-11

    Registered record
    Registry ID
    NCT06055712
    Conditions
    Fractures, Open; Infections
    Interventions
    Cefazolin; Cephalexin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Enrolling by invitation
    Start
    2023-09-11
    Completion
    2034-01
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFractures, Open; Infections
    InterventionCefazolin; Cephalexin
    PhasePhase 4
    Registry statusEnrolling by invitation

  • Comparing Oral Versus Parenteral Antimicrobial Therapy

    NCT05977868 · start 2023-08-04

    Registered record
    Registry ID
    NCT05977868
    Conditions
    Endovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection; Gastrointestinal Infection; Genitourinary Infection
    Interventions
    Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-08-04
    Completion
    2025-02-14
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection +2 more
    InterventionAmoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    PhasePhase 4
    Registry statusTerminated

  • Normothermic Machine Perfusion (NMP) Versus Hypothermic Machine Perfusion (HMP) in Human Kidney Transplantation

    NCT05743751 · start 2023-03-03

    Registered record
    Registry ID
    NCT05743751
    Conditions
    Kidney Transplantation
    Interventions
    Normothermic machine perfusion; Hypothermic machine perfusion
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-03-03
    Completion
    2025-09-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplantation
    InterventionNormothermic machine perfusion; Hypothermic machine perfusion
    PhaseNot applicable
    Registry statusUnknown

  • A Multidisciplinary Perioperative Pain Management

    NCT07150819 · start 2022-07-01

    Registered record
    Registry ID
    NCT07150819
    Conditions
    Anorectal Surgery; Pain Management
    Interventions
    Standard Nursing Care Protocol; MDC-based Pain Management
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2022-07-01
    Completion
    2024-12-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnorectal Surgery; Pain Management
    InterventionStandard Nursing Care Protocol; MDC-based Pain Management
    PhaseNot applicable
    Registry statusWithdrawn

  • Staphylococcus Aureus Network Adaptive Platform Trial

    NCT05137119 · start 2022-02-16

    Registered record
    Registry ID
    NCT05137119
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Cefazolin; Penicillin; Clindamycin; Vancomycin; Effectiveness of early switch to oral antibiotics; Whole body FDG PET/CT Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-02-16
    Completion
    2028-12-01
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionCefazolin; Penicillin; Clindamycin; Vancomycin +2 more
    PhasePhase 4
    Registry statusRecruiting